Wenliang Tan*†1, Sicong Zhu*†1, Jun Cao*†, Lei Zhang*†, Wenda Li*†, Kairui Liu*†, Jinyi Zhong†,
Changzhen Shang*†, Yajin Chen*†
Oncology Research, Vol.25, No.9, pp. 1543-1553, 2017, DOI:10.3727/096504017X14886444100783
Abstract Sorafenib has been globally approved as the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the response rate of HCC patients to sorafenib is limited because of tumor recurrence
and metastasis. Therefore, seeking combined therapeutic strategies with sorafenib is necessary to improve
the antitumor efficiency. Here we demonstrated that expression of MMP-2 is positively correlated with the
migration ability of HCC cells. Cells with a higher MMP-2 expression (SK-HEP-1 cells) were less sensitive
to sorafenib than those with lower MMP-2 expression (HepG2 cells). Cotreatment of cells with SB-3CT and
sorafenib more strongly inhibited… More >
Login
Register
